Duration of diarrhoea · patients symptomatic for NTS infection
1 finding from 1 review
Fever clearance time · patients symptomatic for NTS infection
1 finding from 1 review
Duration of illness · patients symptomatic for NTS infection
1 finding from 1 review
Diarrhoea · patients symptomatic for NTS infection
It is very uncertain whether antibiotics changes presence of diarrhoea at 2‐4 days compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
no estimate extracted
156 participants
Low
Asthma relapse1at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in asthma relapse1at 20 to 24 days compared with oral corticosteroid (high certainty).
1 finding from 1 review
Hoarseness at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hoarseness at 20 to 24 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Asthma relapse1at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in asthma relapse1at 16 to 21 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hoarseness at 16 to 21 days compared with oral corticosteroid (low certainty).
1 finding from 1 review
Intervention not reported
On‐study mortality Death occurring up to 30 days after active study protocol · patients with cancer
The intervention leads to higher on‐study mortality Death occurring up to 30 days after active study… (high certainty).
1 finding from 1 review
Days lost from work Number of people reporting one or more instances of time off work or school · people with asthma
1 finding from 1 review
Mortality (Hospital or 28‐day) · surgical patients
Protocol to increase global blood flow showed no clear difference in mortality (Hospital or 28‐day) compared with control (low certainty).
1 finding from 1 review
Bleeding Number of days with significant bleeding ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days with significant bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Number of days on which a significant bleeding event… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Intervention not reported
Analgesic consumption (day 2) post‐operative · Patients with haemorrhoids
The intervention probably leads to lower analgesic consumption (day 2) post‐operative (moderate certainty).
1 finding from 1 review
28‐Day all‐cause mortality (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in 28‐Day all‐cause mortality (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
Serious bleeding events in adult and paediatric patients (days 0 to 28) · patients with severe sepsis or septic shock
Human recombinant activated protein C probably leads to higher serious bleeding events in adult and paediatric patients (days 0 to… compared with placebo (moderate certainty).
1 finding from 1 review